Seeking Alpha

Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory ...

CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating ...
Business Wire

Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell ...

Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl™ ...
Seeking Alpha

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

SAN FRANCISCO and SUZHOU, China, April 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
KVOA 4

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

At present, no ADC targeting HER2 has been fully approved for first-line treatment of advanced breast cancer in China. There is an urgent need for new drugs to improve the prognosis of patients. About ...
WRIC

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress

On the afternoon of September 27, Academician Binghe Xu from the Cancer Hospital of the Chinese Academy of Medical Sciences gave an oral presentation and paper discussion on the results of the Phase ...
Morningstar

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications ...

FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the efficacy and durability of TOP1 ADCs ...
WLNS.com

Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-threatening ...
Business Wire

Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung ...

WALTHAM, Mass.--(BUSINESS WIRE)--Mythic Therapeutics, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of ...
Morningstar

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...